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Abstract 
A4-amyloid is the major component of senile plaques and neurofibrillary tangles found in the brain of patients uffering Alzheimer's 
disease. This 39-42 amino acid peptide is derived from a larger precursor protein (APP). Since APP gene encodes for a putative 
membrane protein, the study of APP expression at the cell surface may provide useful data for understanding its physiological function. In 
this report, we present data on APP expression, that was detected by APP specific mAbs in cells of the hematopoietic system. APP was 
weakly expressed on the cell surface of resting human lymphocytes and monocytes, but it could be induced to the surface of those cells 
upon stimulation. The cell activators capable of inducing APP membrane xpression comprehended mitogenic lectins, calcium 
ionophores, phosphatase inhibitors, and anti p~-chain or anti-CD3 antibodies in B and T cells, respectively. Interestingly, phorbol esters 
were able to induce APP membrane xpression in monocytic, but not in lymphoid cells. In contrast o lymphocytes and monocytes, 
granulocytes never expressed cell surface or cytoplasmic APP, even after the activation. The induction of membrane APP in response to 
lymphocyte activation signals, including antibodies to the antigen receptor of B and T cells, raises the possibility that APP might play the 
role of a cell surface receptor in the immune system. 
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1. Introduction 
A4-amyloid is the main proteinaceous component of 
senile plaques, aberrant structures characteristically found 
in cerebral parenchyma of patients uffering Alzheimer's 
disease (AD) and, in most cases, around brain blood 
vessels. This 39-42 amino acid peptide is derived from a 
larger precursor protein (APP) and contains 11-14 residues 
of the putative transmembrane domain and 28 of the 
extracellular domain of APP [1]. Although the mechanism 
by which A4-amyloid protein is derived from the precursor 
Abbreviations: AD, Alzheimer's disease; APP, amyloid precursor 
protein; BSA, bovine serum albumin; Con A, concanavalin A; ELISA, 
enzyme linked immunosorbent assay; Ig, immunoglobulin; IL-6, inter- 
leukin-6; mAb, monoclonal antibody; MBP, maltose-binding protein; 
PAGE, polyacrylamide g l electrophoresis; PBS, phosphate-buffered (10 
raM, pH 7.2) saline; PBMC, peripheral blood mononuclear cells; PMN, 
polymorphonuclear cells; PHA, phytohemagglutinin; TNF-et, tumor 
necrosis factor-a. 
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is not completely characterized (for a review, see [2]), 
there seem to be at least two alternative processing path- 
ways for APP: one leading to the secretion of A4 trun- 
cated, nonamyloidogenic fragments [3,4] and the other 
generating amyloidogenic peptides [5-8]. 
The regulation of APP expression and its metabolic fate 
is complex. APP constitutes a family of proteins generated 
by alternative splicing of some of the 19 exons encoded by 
the APP gene [9-14]. Furthermore, APP is also post-trans- 
lationally modified [15] and compartmentalized to ifferent 
cell locations. APP can be processed by multiple prote- 
olytic pathways, leading to APP secretion or intracellular 
degradation. The proteases involved in these proteolytic 
pathways are not sufficiently characterized, but several 
groups are engaged in their elucidation, since they repre- 
sent a potential therapeutic target in AD [16]. APP is 
expressed in almost all the nucleated cell types studied 
[10,15,17-19]. In peripheral blood, APP mRNAs and pro- 
teins have been detected in platelets [20,21] which are 
considered to be the major source of APP in blood [22], 
and in T and B lymphocytes [13]. 
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Although some information is available, the physio- 
logical role of APP remains obscure. Some of the putative 
activities ascribed to APP include receptor activity [15,23], 
cell-cell and cell-extracellular matrix adhesion [24], synap- 
tic function [25], heparin-binding [26] and protease inhibi- 
tion [9,18,27,28]. 
Previous works have shown that APP is synthesized and 
secreted by lymphocytes activated with the cell mitogens 
concanavalin A (Con A) and phytohemagglutinin (PHA) 
[29,30], whereas there are no data on APP expression at 
the membrane of these cells. Since APP is a putative 
transmembrane protein, these data could lead to a better 
understanding of the APP role in the immune system. 
In this report, we have studied APP expression on cells 
of the hematopoietic system, basically focusing on mem- 
brane expression i  response to a variety of cell activators 
including mitogens, phorbol esters, calcium ionophores 
and antibodies pecific for the clonotypic receptor on T 
and B lymphocytes. Herein, we present evidences indicat- 
ing that APP can be considered as a leukocyte activation 
marker, especially in the case of T and B lymphocytes and 
monocytes, because it is induced to the surface of those 
cells by the activation. On the other hand, granulocytes, 
either resting or activated, do not express any detectable 
levels of APP. 
2. Materials and methods 
2.1. Antibodies 
To obtain the APP specific monoclonal antibody (mAb) 
1FH4, Balb/c mice were immunized by i.p. injection with 
a synthetic peptide comprising amino acids 1-42 of A4- 
amyloid (that correspond to amino acids 597-638 of 
APP695), generously provided by Dr. M. Patarroyo (In- 
stituto de Inmunologla, Bogotfi, Colombia). Mice received 
three doses of 50 Ixg of peptide, the first one (at day 0) 
emulsified with complete Freund's adyuvant (1:1 mixture), 
the second one (at day 15) emulsified with incomplete 
Freund's adyuvant and the third one (at day 30) resus- 
pended in PBS. Ten days after the third dose, the presence 
of antibodies pecific for synthetic peptide A4 in mice sera 
was assessed by ELISA. Mice with the highest Ab titer 
were selected and received an i.p. dose of peptide three 
days and one day (50 Ixg each) before sacrifice. Spleno- 
cytes from immune mice were fused to the myeloma 
X63/Ag8653 (NP3) by well established methods [31]. 
Cell hybrids producing antibodies recognizing A4 syn- 
thetic peptide were detected by ELISA and cloned four 
times by LD. This mAb recognizes a synthetic peptide 
covering the amino acids !~-14 of the A4-amyloid peptide 
corresponding to the putative extracellular amino acids 
597-611 of APP isoform 695, both in ELISA and Western 
blot assays (data not shown), as well as recombinant APP 
(Fig. 1). MAb 22C11 was purchased from Boehringer- 
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Fig. 1. IFH4 mAb recognition of recombinant APP. E. coli cells induced 
to express recombinant MBP-APP770 fusion protein were subjected to 
SDS-PAGE under reducing conditions (750 Ixl of culture per lane) and 
immunoblotting with purified IFH4 mAb (I p.g/ml), 22C11 (5 Ixg/ml) 
or an irrelevant (Control) mAb (5 Ixg/ml). The full-length fusion protein 
MBP-APP770 (mol. mass around 170 kDa), stained by both anti-APP 
mAbs, is indicated by an arrow. Bands below this one, recognized only 
by mAb 22CI1, represent intermediate forms of the fusion protein. 
Molecular mass markers (M) were, from top to bottom: 200, 116 and 97 
kDa. 
Mannheim and reacts to an epitope of the APP molecule 
also located in the putative xtracellular part of APP but 
outside the A4 peptide, around amino acids 66-81 [32]. 
Mab 7BB5 was obtained with the same strategy than 
1FH4, using a synthetic peptide covering amino acids 
676-690 of APP695 (located in the putative intracytoplas- 
mic domain of APP) for mice immunization and hy- 
bridoma screening; 7BB5 recognizes the immunizing pep- 
tide as well as the full-length recombinant fusion protein 
MBP-APP (data not shown). The mAb SPVT3b, specific 
for CD3, was a generous gift from Dr. J. de Vries. The 
mAbs specific for cell surface markers: MAR 108 (anti- 
CD25), Mo-I (anti-CDl b) and Mo-2 (anti-CD1 lc) were 
generously supplied by Dr. Francisco Sfinchez-Madrid and 
Miguel L6pez-Botet, Hospital de la Princesa, Madrid. The 
mAb DA4.4 (anti IgM) and THB-5 (anti CD21) were 
obtained from the ATCC. Fluorescein labeled rabbit anti 
mouse Igs was purchased from Southern Biotechnology 
and biotin labeled sheep anti-mouse IgG and streptavidin- 
horseradish peroxidase were obtained from Boehringer- 
Mannheim. 
2.2. Cells 
The different human leukocyte subpopulations were 
obtained from blood of healthy donors basically as de- 
scribed [33]. Briefly, human peripheral blood mononuclear 
cells (PBMC) were obtained from heparinized venous 
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blood of normal volunteers by centrifugation over Ficoll 
Hypaque (Pharmacia Fine Chemicals, Uppsala, Sweden). 
The layer containing PB/~IC cells was taken and the cells 
washed thoroughly by centrifugation in DMEM. 
Macrophage and lymphocyte populations were separated 
by adherence to plastic dishes for 2 h at 37°C according to 
standard methods, washed with serum-free medium and 
resuspended in DMEM supplemented with 2% FCS. Poly- 
morphonuclear cells (PMN) were obtained from the pellet 
of Ficoll centrifugation and separated from red cells by 
hypotonic shock. In all cases, cell viability, determined by 
trypan blue dye exclusion, was > 99%. Purity of the 
different cell populations was determined by immunofluo- 
rescence with antibodies pecific for each cell type and 
was always > 95%. 
All cell lines were obtained from ATCC. The Jurkat T 
cell lymphoma, U937 monocytic and HL-60 promyelocytic 
cell lines were cultured in RPMI medium supplemented 
with 5-10% FCS. 
incubation were determined for each stimulus and it is 
indicated in each experiment. 
2.6. Immunofluorescence flow cytometry 
After stimulation, the cells were washed three times in 
PBS with 2% FCS. They were subsequently incubated 
with mAbs (undiluted hybridoma culture supernatant ex- 
cept for 22C 11 mAb, which was used in purified form at 5 
Ixg/ml) for 30 min at 4°C. Cells stimulated with mAbs 
(anti-Ix and anti-CD3) were subjected to acid treatment 
before the washing above described in order to detach the 
stimulating antibodies, according to standard methods. 
Treatment effectiveness was monitored by the absence of 
unspecific (irrelevant antibody) fluorescent staining of 
those cells. Subsequently, cells were washed in the above 
buffer and incubated again with rabbit anti-mouse Ig-FITC 
for 30 min at 4°C. Surface fluorescence was determined in
an EPICS spectrofluorimeter. 
2.3. Lymphokines 2.7. Preparation of total and subcellular cell extracts 
Recombinant human interleukin-6 (IL-6) was a gener- 
ous gift of Dr. Walter Fiers, University of Ghent, Belgium, 
and recombinant human tumor necrosis factor- (TNF-) was 
a gift of Antibi6ticos-Farma (Madrid, Spain). Nerve growth 
factor (NGF) was purified from rat brain extracts accord- 
ing to the described methods [34]. 
2.4. Recombinant APP 
The three major APP isoforms were expressed in Es- 
cherichia coli using the pMal plasmid from New England 
Biolabs, which yields proteins fused to maltose-binding 
protein (MBP). cDNA clones pSP65, generously donated 
by Dr. Beyreuther, were used to construct he plasmids 
pMalc-695, pMalc-751 and pMalc-770, pSP65-APP vec- 
tors were digested with the restriction enzyme BamI, 
recessed 3' termini filled with Klenow fragment and fi- 
nally subjected to a HindlII digestion, pMalc(plH821) 
vector was digested with the restriction enzymes StuI and 
HindlII. The ligation mixture of each of the three APP- 
cDNAs with the digested pMal~ vector was used to trans- 
form competent E. coli TG1 cells. Cells containing plas- 
mids that coded for fusion proteins were grown and in- 
duced with isopropyl thio-13-D-galactosidase. Bacterial cells 
were sedimented by low-speed centrifugation and directly 
resuspended in SDS-PAGE sample buffer. 
2.5. Cell activation 
Cells were resuspended at a density of 2 • 10  6 per ml in 
DME supplemented with 2% FCS and incubated at 37°C 
in 7% CO 2 atmosphere in the absence or presence of 
different stimuli. Time and dose response curves were 
made (data not shown); the optimal dose and time of 
Total cell extracts were prepared by incubation in Tris- 
HC1 10 mM pH 8.0, NaC1 150 mM containing 0.5% 
NP-40 and protease inhibitors (PMSF 1 mM, aprotinin 0.5 
Ixg per ml, leupeptin 50 IXM, pepstatin 1 IXM and EDTA 2 
mM) for 30 min, on ice. Cell extracts were centrifuged at 
12 000 × g for 15 min. 
Subcellular f actions were obtained by Dounce homoge- 
nization as described [35]. Briefly, cells were resuspended 
in a hypotonic buffer: Tris-HC1 10 mM pH 7.6, containing 
0.5 mM MgC12 and protease inhibitors (50 IXM leupeptin, 
1 mM PMSF and 1 /xM pepstatin) and passed 30 times 
through the Dounce, followed by a tonicity restoration to 
0.15 M NaC1. After centrifugation at 800 X g for 5 min, 
an insoluble (nucleus plus partially disrupted cells) and 
soluble fraction were obtained. Soluble fraction was cen- 
trifuged at 12 000 X g, thus obtaining an insoluble (plasma 
membrane) and soluble (cytoplasmic) fractions. 
Cytoplasmic fraction was suplemented with EDTA pH 
7.6 to 0.5 M, and centrifuged at 150000 X g for 45 min, 
obtaining an insoluble (internal membranes) and soluble 
(cytosolic) fractions. All the fractions were completed to 
100 ml with hypotonic buffer. Samples were stored at 
- 20oc. 
2.8. Western blot 
Proteins were separated by SDS-PAGE under reducing 
conditions and transferred to nitrocellulose membranes. 
Non-specific reactivity was blocked by overnight incuba- 
tion at 4°C with BSA 3%/Tween-20 .2%. After incuba- 
tion at room temperature for 2 h with specific mAbs, the 
bound Ab was detected with biotinylated sheep anti-mouse 
Ig, followed by streptavidin-horseradish peroxidase. Blots 
were developed using the ECL system (Amersham). 
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2.9, Amplification of APP mRNA (RT-PCR) 
Total RNA was extracted from peripheral blood lym- 
phocytes and granulocytes according to the described 
methods ([36,37] respectively), cDNA was obtained from 1 
mg of total RNA, using oligo (dT)16 primer and 'Moloney 
Murine Leukemia Virus (M--MLV) Reverse Transcriptase' 
(Perkin Elmer; GeneAmp RNA PCR Ki0, according to 
manufacturer's specifications. 
Amplification of APP from the cDNAs was carried out 
with 'Taq Polymerase' (Perkin Elmer), using an oligo- 
nucleotide pair flanking APP exon 15, obtained from 
ISOGEN Bioscience, (APPU: CCGTGGAGCTCCTTCC- 
CGTG (nucleotides 1808--1827 of human APP/770 
mRNA); APPL: TAGCCGTTCTGCTGCATCTTGG 
(nucleotides 2249-2270 of human APP/770 mRNA)), in 
a Gene Amp PCR System 9600 (Perkin Elmer) termocy- 
cler, according to the following temperature pattern: denat- 
uration at 95°C for 2 min; 35 cycles of denaturation at
95°C for 1 min and annealing/extension at 55°C for 1 
min; final extension at 60°(: for 7 rain. 
As a control, a 420 bp fragment of IL-lot mRNA was 
subjected to reverse tran,;cription and amplified using 
oligonucleotides included in the RNA PCR Kit. 
3. Results 
3.1. APP expression at the membrane of leukocytes 
Very little is known about the physiological roles of 
APP. Since APP gene encodes for a putative membrane 
protein, it is of high interest to study cell surface expres- 
sion of APP in order to understand its physiological func- 
tion. Flow cytometry analysis with specific antibodies 
allows easy and reliable detection of cell surface proteins. 
In line with this, we have wanted to find out whether a 
newly developed mAb (IFH4), recognizing amino acids 
597-611 of the APP695 molecule, can also recognize APP 
in human leukocytes, either esting or activated by agents 
modulating different biochemical pathways. 
As shown in Table 1, neither lymphocytes, nor mono- 
cytes, nor granulocytes purified from peripheral blood of 
healthy human volunteers expressed significant amount of 
the APP epitope detected by 1FH4 mAb on the cell 
surface. Interestingly, the great majority of lymphocytes 
(70%) stimulated for 48 h with T-cell mitogens uch as 
PHA strongly expressed IFH4 epitope in the cell surface. 
This expression was even stronger than that detected with 
antibodies pecific for IL-2R, a typical T cell activation 
molecule. Lymphocytes also expressed IFH4 epitope on 
the cell surface upon activation of B cells with an anti-IgM 
mAb. Since PBL cells comprehend roughly 30% B cells 
and 70% T cells, those results indicate that most T and, at 
least, a population of B cells express cell surface APP 
upon appropriate stimulation. Moreover, a population of 
monocytes timulated for 48 h with LPS also strongly 
expressed the 1FH4 epitope. By contrast, granulocytes 
stimulated with the chemoactive peptide f-Met-Leu-Phe 
(FMLP) did not express 1FH4 epitope at all (Table 1). 
In order to discard the possibility that fluoresecent 
staining with 1FH4 could be due to the recognition of 
cross-reactive proteins or of small A4 containing peptides, 
we used another anti-APP mAb, 22C 11, which recognizes 
an epitope located on the N terminus (amino acids 66-81) 
of the APP695 molecule, far away from the A4 region 
[32]. Basically, qualitatively similar expression patterns 
were found with both antibodies in response to various 
Table 1 
APP membrane expression by human hemopoietic cells 
Cell type a Cell surface xpression (percent positive cells/mean fluorescence, A.U.) b 
resting cells activated cells 
APP(A4) c activation marker d APP(A4) activation marker 
Lymphocytes (T) 0 /0  6/20 72/45 35/34 
Lymphocytes (B) 6/68 7/46 15/92 30/51 
Monocytes 3 / 19 86/31 19/41 95/74 
Granulocytes 2/11 95/88 3/9 100/210 
a Lymphocytes, monocytes and granulocytes were obtained from human peripheral blood and incubated (2 • 106/ml) in the absence (resting cells) or 
presence (activated cells) of diflerent stimuli as indicated in Section 2. In order to specifically stimulate T or B cells, total lymphocyte population was 
incubated for 48 h with 10 Ixg of PHA (T) or 10 Ixg of the ix-chain specific mAb (B) per ml, respectively. Monocytes were stimulated with 10 ixg/ml LPS 
for 48 h. Granulocytes were incubated for 15 min in the presence of 1 ixM FMLP. 
b Cell surface expression, determined by indirect immunofluorescence, is presented as the percentage of positive ceils (cells with a fluorescence higher 
than a limit established by usin~g an irrelevant, isotype-matched (control) mAb), followed by the mean fluorescence of positive cells in arbitrary units. 
(Flow cytometry units are values proportional to the electrical signals generated by the photodetectors.) Values from a representative experiment are 
shown. Variations in the percentage of positive cells between experiments were less than 15%. 
c APP expression was determined with mAb 1FH4. 
d Cell activation was monitored by immunofluorescence with mAbs specific for the following activation markers: CD 25 for T lymphocytes; CD21 for B 
lymphocytes and CD1 lb for myelomonocytic cells (monocytes and granulocytes). 
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Table 2 
Induction of APP membrane expression on human lymphocytes 
Acivation a Cell surface xpression 
(percent positive cells/mean fluorescence, A.U.) b 
antibody 
1FH4 22C 11 anti-CD25 
None 0/0 0/0 5/20 
PHA 72/45 33/15 40/34 
anti-CD3 36/13 15 / 10 20/10 
PBu2 4/20 2/18 75/46 
Okadaic acid 27/52 ND 32/14 
A23187 55/297 ND 50/30 
Lymphocytes from human peripheral blood were incubated for 48 h 
with: 10 ixg of PHA, 1 Izg of anti-CD3 mAb, 25 ng/ml of PBu2, 1 tzM 
okadaic acid or 1 IxM A23187. APP expression was determined by 
indirect immunofluorescence with mAbs 22C11 and 1FH4. 
b As in Table 1. T cell activation was monitored with an anti-CD25 
mAb. 
stimuli, although 22C l 1 roughly detected only half of the 
cells than 1FH4 did (Table 2); we cannot account for this 
difference yet, but it may be due to different accesibility of 
the corresponding epitopes to the mAbs. Taken together, 
these data strongly suggest that the full-length APP 
molecules, or at least large N-terminal fragments, were 
expressed on the cell surface of T lymphocytes. 
3.2. Effect of different cell activators on APP membrane 
expression by peripheral blood lymphocytes 
We further analyzed the effect of different stimuli on 
the induction of APP expression on lymphocytes. Activa- 
tion of T lymphocytes through the antigen receptor by 
anti-CD3 mAb or mitogenic lectins, such as PHA (Table 
2) or Con A (data not shown), was able to induce APP on 
the cell surface of purified lymphocytes. APP expression 
showed a dose response curve and kinetics similar to that 
of IL-2R. Thus, membrane APP was barely detected 4 h 
after activation with PHA and its expression was at its 
maximum at 48 h, decaying from then until 72 h, the 
longest ime point analyzed (data not shown). 
Activation of T lymphocytes is thought to require an 
increase in intracellular Ca 2+' as well as an activation of 
PKC,  which can be mimicked by calcium ionophores and 
phorbol esters, respectively. In order to discriminate which 
of these two signals was required to induce APP expres- 
sion, lymphocytes were treated with the calcium ionophore 
A23187, or with phorbol esters (PBu2 or PMA (not 
shown)), and APP expression was tested. As summarized 
in Table 2, doses of PBu2 able to induce higher IL-2R 
levels than PHA were unable to induce APP surface 
expression, whereas A21387 was as good inducer of APP 
as mitogenic lectins. These results suggest hat an increase 
in intracellular Ca 2+ was sufficient o induce APP expres- 
sion on the cell surface. Moreover, phosphorylat ion/ de- 
phosphorylation mechanisms should be involved, either by 
direct or indirect mechanisms, in APP expression, as its 
surface expression was also induced by okadaic acid, an 
inhibitor of the protein phosphatases 1 and 2A. 
3.3. Differential effects of phorbol esters on APP mem- 
brane expression by lymphoid and monocytic ell lines 
In order to reinforce the above data, cell lines of 
lymphoid or monocytic lineages were stimulated with the 
same cell activators. As shown in Table 3, the results were 
in perfect agreement with that obtained with peripheral 
blood cells. Thus, Jurkat, a T cell lymphoma, or U937, a 
monocyte-like cell line, did not constitutively express APP 
(neither the 1FH4 nor 22C11 (data not shown) epitopes) 
on their cell surface. However, Jurkat cells expressed 
surface APP when they were stimulated with PHA or 
calcium ionophore A23187, but not with the phorbol esters 
PMA or PBu2 (not shown). By contrast, phorbol esters 
were able to induce a significant APP expression on the 
monocytic ell line U937, indicating that the second mes- 
sengers involved in the regulation of APP expression are 
dependent on the cell type. Interestingly, the inflammatory 
cytokine TNF was also able to induce APP expression in 
Jurkat or U-937 cell lines. It is worth noting that all those 
stimuli also induced differentiation/activation of ceils. 
3.4. Effect of different cell activators on APP membrane 
expression by granulocytes 
In contrast o lymphocytes and monocytes, granulocytes 
did not express APP, even after stimulation with a variety 
of stimuli including the potent physiologic stimulus FMLP. 
Proinflammatory cytokines, such as TNF or IL-6, and 
phorbol esters were also unable to induce APP on those 
Table 3 
APP expression atthe membrane ofhuman lymphoid and monocytic cell 
lines 
Cell activation a Cell surface xpression 
(percent positive cells/mean fluorescence, A.U.) h 
Jurkat U937 
APP(A4) CD25 APP(A4) CD 11 b 
None 2,/34 1/24 2/59 6/15 
PHA 20/202 20/43 ND ND 
A23187 14/276 24/50 ND ND 
PMA 1/35 12/40 27/125 15/38 
TNF 14/40 15/42 67/86 40/17 
a Jurkat and U937 cells (2. 106/ml) were cultured for 24 h in medium 
alone or in the presence of 10 txg/ml of PHA, 1 I,LM of A23187, 10 
ng/ml of PMA or 100 U/ml of TNF. 
b APP expression was determined by indirect immunofluorescence with
mAb 1FH4. Cell activation/differentiation wasmonitored with mAbs 
specific for CD25 (MAR108) or CDI lb (Mo-l) for Jurkat and U937 
cells, respectively. 
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Table 4 
Induction of APP membrane expression on human granulocytes 
Activation a Cell surface xpression (percent positive 
cells/mean fluorescence, A.U.) 
APP b CDl lb  
None 2/11 95/88 
FMLP 3 /9  100/210 
PBu2 1/14 100/235 
TNF 1/20 100/189 
IL-6 0 /0  100/150 
NGF 2/11 100/242 
Human peripheral blood granulocytes were incubated for 30 min in 
medium alone or in the presence of 1 txM FMLP, 25 ng/ml  PBu2, 100 
U /ml  IL-6, 200 U /ml  TNF or 5ll ng /ml  NGF. 
b APP expression was determined by indirect immunofluorescence with 
mAbs 22C11 and IFH4. Both are represented with the same numbers 
since their staining was identical. Cell activation was monitored with an 
anti-C1 lb mAb. 
cells (Table 4) even after incubation for prolonged periods 
of time (up to 12 h). By contrast, all of these activators 
greatly augmented the cell surface xpression of the activa- 
tion marker CD1 lb, what resulted in a great increase of the 
mean fluorescence intensity. The above results strongly 
suggest hat granulocytes were the only major leukocyte 
cell type that does not express membrane APP. 
To confirm these data the HL-60 cell line was used. 
This cell line can be differentiated into the 
monocyte/macrophage lin age by stimuli such as PMA, 
or to granulocyte lineage by stimuli such as retinoic acid 
(RA) [38]. The results, shown in Table 5, confirmed the 
data obtained with peripheral blood cells. HL-60 did not 
constitutively express urface APP. After stimulation with 
PMA, HL-60 cells differentiated to monocytes, as indi- 
cated by an increased cell surface xpression of markers of 
the monocytic lineage (CD1 lb,c), and APP expression was 
also induced, although in a small percent of the cells. By 
contrast, treatment of HL-60 cells with RA induced their 
differentiation i to granulocytes, as detected by the cell 
surface expression of CD1 lb and not of CDllc. As ex- 
pected, APP expression after the RA treatment remained 
below the detection limit of this technique. 
3.5. APP protein and mRNA detection in lymphocytes and 
granulocytes 
In order to characterize more clearly the APP species 
recognized by mAb 1FH4 in lymphoid cells, Jurkat cells 
were lysed and the Ags recognized by IFH4 were detected 
by Western blotting (Fig. 2). IFH4 mAb and, although 
more weakly, 22C11 and 7BB5 (which reacts to a peptide 
located in the putative intracytoplasmic region of APP) 
(not shown), stained a 95 kDa band that was expressed to 
similar levels in cells cultured either in the absence ( - )  or 
presence (+)  of PHA. These data suggest hat lympho- 
cytes, together with the 'mature' 120-140 kDa APPs, 
which were stained by 22C11 and 7BB5, express a full- 
length, 95 kDa APP. Similarly to our results, full-length 
APP molecules with molecular masses of 94-98 kDa have 
been identified as newly sinthesized forms [15,39,40], and 
APP moieties howing this electrophoretic mobility have 
been described either in lymphoid [29] or non lymphoid 
tissues [39] with different anti-APP antibodies. The fact 
that 'mature' forms of cellular APP were not detected by 
IFH4, wich, in contrast, did recognize full-length APP 
expressed in a bacterial system (see Fig. 1) can be at- 
tributed to a masking of the epitope in the cellular forms, 
as has been reported for other anti-APP Abs [39]. 
In contrast to lymphocytes, we failed to detect APP on 
granulocytes, either resting or activated with FMLP (Fig. 
2), PBu2, TNF, IL-6 or NGF (data not shown), even after 
12 h incubations. 
Furthermore, when the expression of APP-mRNA in 
peripheral blood lymphocytes and granulocytes was inves- 
tigated (Fig. 3), results clearly confirmed the data observed 
at protein level. Thus, lymphocyte RNA amplification with 
APP specific primers rendered two PCR bands of 462 
lAPP) and 408 (L-APP) base pairs, corresponding to exon 
15 alternatively spliced forms [14]; in addition, an induc- 
Table 5 
Induction of APP membrane expression on HL-60 myelomonocytic cells 
Acivation a Cell surface xpression 
(percent positive cells/mean fluorescence, A.U.) 
antibody b 
1FH4 anti-CD 11 b anti-CD 11 c 
None 2/20 20/20 2/32 
PMA 16/54 70/37 79/31 
Retinoic acid 2 /56 70/29 15/16 
a Undifferentiated HL-60 cells were incubated for 24 h in the presence of 
10 ng/ml  of PMA or 1 Ixg/ml retinoic acid, or in medium alone. 
b APP expression was determined by indirect immunofluorescence with 
mAb 1FH4. Cell activation/differentiation was monitored with anti 
CDI lb and CD1 lc mAbs. 
M 
I 
l u rkat  Granu locytes  
- + - -  + 
Fig. 2. APP expression in human hemopoietic cells. Cell extracts from 
Jurkat cells and peripheral blood granulocytes were prepared as described 
in Section 2 after being culture under the following conditions: Jurkat 
cells were grown for 24 h in medium without ( - ) or with (+)  10 ixg/ml 
PHA. Granulocytes were cultured for 30 min in medium alone ( - )  or in 
the presence of 1 p,M FMLP ( + ). Cells were lysed and APP expression 
was determined by Western blot with 1FH4 mAb as described in Section 
2. Molecular mass markers (M) were, from top to bottom, 97 and 70 kDa. 
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Lymphocytes Granulocytes 
-- + + 
M APP IL-1 APP IL-1 APP IL-1 
Fig. 3. APP mRNA expression by human lymphocytes and granulocytes. 
Total RNA was extracted from human peripheral blood lymphocytes 
cultured for 24 h in medium without ( - )  or with (+)  10 p.g/ml PHA, 
and from granulocytes cultured for 18 h in the presence of 6 ng/ml  PMA 
( + ). The presence of APP mRNA was detected by PCR as described in 
Section 2. As a control, primers for IL-I were used. Molecular mass 
markers (M) were, from top to bottom, 1330, 1150, 760, 611(579) and 
453 bp. 
tion of expression in response to activation with PHA was 
observed [41]. By contrast, no APP-mRNA was detected in 
granulocytes incubated in the absence (not shown) or 
presence of different stimuli, which were functional since 
they induced the expression of molecules uch as IL-1OL 
mRNA [42]. 
3.6. Subcellular distribution of the APP molecule recog- 
nized by 1FH4 mAb 
In order to determine the location of the 95 kDa protein 
recognized by 1FH4 in lymphocytes, a subfractionation f 
M C ontrol Activated 
a b c a b c 
m 
Fig. 4. APP location to subcellular fractions of lymphoid cells. Jurkat 
cells were cultured in the same conditions as in Fig, 2. Subcellular 
fractions were prepared by using various steps of solubilization and 
centrifugation as described in Section 2. Proteins corresponding to 3.106 
cells were subjected to electrophoresis and Western blot with 1FH4 mAb. 
Results for 12000x g insoluble (plasma membrane) (a), 150000X g 
soluble (b) and 150000X g insoluble (c) fractions are shown. Molecular 
mass markers (M) were, from top to bottom, 97 and 70 kDa. 
Jurkat cells, followed by Western blot of the different 
fractions, was carried out. The results are shown in Fig. 4. 
Subcellular location of the 95 kDa band was in good 
agreement with the reported subcellular distribution of 
APP for different cell types [5,12]. Thus, it was more 
abundant in organelles, followed by the 150000 X g solu- 
ble fraction and cytoplasmic membrane. On the other 
hand, the 95 kDa band was stained in Western blot of 
cytoplasmic membranes by both 22Cll and 7BB5 (data 
not shown), indicating that this molecule was, in fact, 
full-length APP. Although these experiments do not allow 
to discard the possibility of detection of proteins trapped 
within the fractionated membranes, the fact that the 95 
kDa protein displays both putative intracellular and extra- 
cellular domains of APP strongly suggests that membrane 
expression, detected by cytofluorimetry, is not due to a 
non-specifically bound protein, what is in good agreement 
with the possibility of this molecule being recognized by 
1FH4 and 22C 11 immunofluorescent staining. On the other 
hand, the relative abundance of the 95 kDa band in the 
membrane compared to organelles was higher in the acti- 
vated than in the resting cells, what further agrees with the 
observation of an APP membrane induction detected by 
immunofluorescence. Further experiments should be car- 
ried out to elucidate the way this molecule is located to the 
cell membrane, as well as to determine its biological role 
in lymphocytes. Another possibility, which we cannot 
discard using mAbs, is that the protein stained by immuno- 
fluorescence is 'mature' 120-140 kDa APP which is not 
stained in Western Blot by 1FH4 due to structural prob- 
lems, such as epitope 'masking'. 
4. Discussion 
Despite increasing evidence for a pathogenic role of 
APP in Alzheimer's disease, the physiological role of the 
protein remains unclear. The study of factors affecting 
APP expression in different cells can provide useful data 
to clarify APP normal function as well as the mechanisms 
leading to A4-amyloid formation. The neural and blood 
cells are of particular interest, since most of the studies 
support either a neuronal or vascular source for A4- 
amyloid. Furthermore, abnormal and deficient processing 
of APP has been described in familial Alzheimer's disease 
lymphoblastoid cells [43,44]. However, we have not ob- 
served significant differences in membrane APP expres- 
sion between AD patients and normal individuals (unpub- 
lished results). Whereas APP expression regulation in neu- 
ronal and glial cells is well documented, APP expression 
in blood cells, particularly lymphocytes and granulocytes, 
has been scarcely studied [13,41,45]. 
The results presented herein confirm and extend previ- 
ous data reporting APP synthesis by lymphocytes and 
monocytes, and show that APP could be considered as a 
cell surface activation Ag of T and B lymphocytes and a 
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population of monocytes. Nevertheless, the results pre- 
sented do not allow us to determine if APP is directly 
inserted in the cell membrane or bound through a receptor. 
However, two sets of data, not excluding the second 
possibility, strongly suggest that the first is more probable: 
First, molecules displaying two distant APP epitopes of the 
extracellular domain are stained by antibodies in intact 
cells; the fluorescent s aining remains (see Tables 1 and 2) 
in cells stimulated by the anti-ix and anti-CD3 antibodies 
after an acid treatment whiLch detaches proteins, like the 
stimulating antibodies, bound to the membrane through 
specific receptors with high affinity; all this indicates that 
the molecule is not likely to be bound to a receptor. 
Second, the 95 kDa band, stained in Western Blot of 
cytoplasmic membrane fr~ctions by IFH4, 22Cll and 
7BB5, seems to be a full-length APP, or, at least, it 
displays both putative extracellular and intracytoplasmic 
APP domains; consequently, the most probable possibility 
would be that the molecule is, in fact, spanning the cell 
membrane. 
The induction of membrane APP in response to lym- 
phocyte activation signals including TcR is consistent with 
a role of this protein in the immune system as suggested 
[14]. Since APP has the properties of a cell adhesion 
molecule, it may have a role of a surface receptor involved 
in cell adherence, cell-cell contact or cell-extracellular 
matrix contact. Such a role has been shown for APP in 
neuronal cells [24,46,47]. Alternatively, APP expression on 
lymphocyte membrane m~y be an intermediate step for 
secretion, which has been shown to be induced by lectin 
stimulation of peripheral blood T lymphocytes [30]. In this 
regard, it would be similar to other cell activation molecules 
such as TNF, which is first synthesized as membrane 
anchored TNF and then cleaved by specific proteases and 
released to the medium [48]. Additional experiments would 
be necessary to distinguish between these different possi- 
bilities. 
The fact that PKC activators induce membrane APP in 
monocytic but not lymphoid cells indicates that the regula- 
tion of APP expression varies according to the cell type, 
involving different second messengers for each cell type. 
Whereas the role of PKC on APP expression has been 
analyzed in neuronal cell lines like PC-12, where it has 
been shown to phosphorylate APP and regulate its expres- 
sion and secretion [49], there are no data on other cell 
types. Since it has been clearly shown that APP isoforms 
are differentially distributed in different cell types [14], 
PKC could have differential effects on the APP isoforms 
expressed in each cell type. Moreover, since the inhibition 
of phosphatases with okadaic acid and the increase of 
intracellular concentration f Ca 2+ induced APP, it seems 
likely that tyrosine phosphorylation, that activates PLC-~/ 
in T lymphocytes, may lead to Ca 2÷ increase and subse- 
quent APP membrane expression. Nevertheless, the analy- 
sis of the signaling pathways involved in the regulation of 
APP expression deserves further studies. 
Strikingly, granulocytes could not be induced to synthe- 
size detectable vels of APP, neither protein nor mRNA, 
thus remaining the only major blood cell type that does not 
express the molecule. Since granulocytes present many 
proteolytic activities, this result raises the intriguing possi- 
bility that granulocyte specific protease(s) could be in- 
volved in APP amyloidogenic proccessing. Our results are 
in contrast o recent studies showing that APP lacking 
transmembrane and cytoplasmic domains is present at low 
levels in azurophilic granules of granulocytes. Neverthe- 
less, these studies do not exclude the possibility that APP 
is not synthesized by granulocytes, but internalized from 
the blood [50]. 
Inflammatory cytokines uch as TNF, that play a rele- 
vant role in the activation of the nervous ystem [51], also 
induced APP expression on lymphocyte membrane. Recent 
investigations have demonstrated a local inflammatory re- 
sponse, and elevated circulating levels of cytokines, such 
as IL-1 and TNF, have been described in AD. [52]. Fur- 
thermore, IL-6 and IL-1 stimulated the synthesis of APP 
[53]. This gives support o the hypothesis that an acute 
phase response initiated by IL-I or TNF acting through 
IL-6 could be responsible, by inducing APP expression, of 
accelerated rates of A4 deposition in AD brain. In fact, a 
recent pilot study shows that the anti inflammatory drug 
indomethacin appeared to slow the progress of the disease 
[54]. Since A4 is derived from APP by physiological 
proteolytic processing [17], it is likely that conditions 
leading to over-expression f APP result in over-produc- 
tion of A4. Thus, chronic upregulation of APP could be a 
cause of amyloid deposition in AD. This further strength- 
ens the need to study the factors that regulate normal APP 
expression. 
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